Anna Secher

Anna Secher

Auto-generated profile, based on publicly available information

Anna Secher

Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
MLMette Q. Ludwig
Mette Q. Ludwig
WCWenwen Cheng
Wenwen Cheng
DGDesiree Gordian
Desiree Gordian
JLJulie Lee
Julie Lee
SPSarah J. Paulsen
Sarah J. Paulsen
TPTune H. Pers
Tune H. Pers

20 December 2021 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
MKMarta Porniece Kumar
Marta Porniece Kumar
ACAnna Lena Cremer
Anna Lena Cremer
PKPaul Klemm
Paul Klemm
LSLukas Steuernagel
Lukas Steuernagel
SSSivaraj Sundaram
Sivaraj Sundaram
JBJens C. Brüning
Jens C. Brüning
Insulin acts on neurons and glial cells to regulate systemic glucose metabolism and feeding. However, the mechanisms of insulin access in discrete brain regions are incompletely defined. Here we show that insulin receptors in tanycytes, but not in brain endothelial cells, are required to regulate insulin access to the hypothalamic arcuate nucleus. Mice lacking insulin receptors in tanycytes (IR∆Tan mice) exhibit systemic insulin resistance, while displaying normal food intake and energy expenditure. Tanycytic insulin receptors are also necessary for the orexigenic effects of ghrelin, but not for the anorexic effects of leptin. IR∆Tan mice exhibit increased agouti-related peptide (AgRP) neuronal activity, while displaying blunted AgRP neuronal adaptations to feeding-related stimuli. Lastly, a highly palatable food decreases tanycytic and arcuate nucleus insulin signalling to levels comparable to those seen in IR∆Tan mice. These changes are rooted in modifications of cellular stress responses and of mitochondrial protein quality control in tanycytes. Conclusively, we reveal a critical role of tanycyte insulin receptors in gating feeding-state-dependent regulation of AgRP neurons and systemic insulin sensitivity, and show that insulin resistance in tanycytes contributes to the pleiotropic manifestations of obesity-associated insulin resistance.

3 January 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LMLasse Maretty
Lasse Maretty
DGDipender Gill
Dipender Gill
LSLotte Simonsen
Lotte Simonsen
KSKeng Soh
Keng Soh
LZLoukas Zagkos
Loukas Zagkos
MGMilan Geybels
Milan Geybels
Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 (n = 1,311) and STEP 2 (n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways. Several proteins were regulated with semaglutide, after accounting for changes in body weight and HbA1c at end of trial, suggesting effects of semaglutide on the proteome beyond weight loss and glucose lowering. A comparison of semaglutide with real-world proteomic profiles revealed potential benefits on disease-specific proteomic signatures including the downregulation of specific proteins associated with cardiovascular disease risk, supporting its reported effects of lowering cardiovascular disease risk and potential drug repurposing opportunities. This study showcases the potential of proteomics data gathered from randomized trials for providing insights into disease mechanisms and drug repurposing opportunities. These data also highlight the unmet need for, and importance of, examining proteomic changes in response to weight loss pharmacotherapy in future trials.

7 September 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMarie A. Bentsen
Marie A. Bentsen
DRDylan M. Rausch
Dylan M. Rausch
ZMZaman Mirzadeh
Zaman Mirzadeh
KMKenjiro Muta
Kenjiro Muta
JSJarrad M. Scarlett
Jarrad M. Scarlett
TPTune H. Pers
Tune H. Pers
In rodent models of type 2 diabetes (T2D), sustained remission of hyperglycemia can be induced by a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1), and the mediobasal hypothalamus (MBH) was recently implicated as the brain area responsible for this effect. To better understand the cellular response to FGF1 in the MBH, we sequenced >79,000 single-cell transcriptomes from the hypothalamus of diabetic Lepob/ob mice obtained on Days 1 and 5 after icv injection of either FGF1 or vehicle. A wide range of transcriptional responses to FGF1 was observed across diverse hypothalamic cell types, with glial cell types responding much more robustly than neurons at both time points. Tanycytes and ependymal cells were the most FGF1-responsive cell type at Day 1, but astrocytes and oligodendrocyte lineage cells subsequently became more responsive. Based on histochemical and ultrastructural evidence of enhanced cell-cell interactions between astrocytes and Agrp neurons (key components of the melanocortin system), we performed a series of studies showing that intact melanocortin signaling is required for the sustained antidiabetic action of FGF1. These data collectively suggest that hypothalamic glial cells are leading targets for the effects of FGF1 and that sustained diabetes remission is dependent on intact melanocortin signaling.

1 May 2020 in Neuropharmacology
Verified
Journal Article
Closed access
HZHannah Louise Zakariassen
Hannah Louise Zakariassen
LJLinu Mary John
Linu Mary John
Jens LykkesfeldtJens Lykkesfeldt
Jens Lykkesfeldt
KRKirsten Raun
Kirsten Raun
TGTine Glendorf
Tine Glendorf
CFChristelle Le Foll
Christelle Le Foll

8 July 2025 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
JJJulie Mie Jacobsen
Julie Mie Jacobsen
JHJens Frey Halling
Jens Frey Halling
IBIda Blom
Ida Blom
JMJaime Moreno Martinez
Jaime Moreno Martinez
BHBjørn Hald
Bjørn Hald
RKRune E. Kuhre
Rune E. Kuhre
CagriSema is a combination of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide) analogues being developed for weight management. Here, we show that CagriSema blunts metabolic adaptation in rats. Quantifying CagriSema’s action on energy intake and expenditure in rats we observe 12% weight loss with a 39% reduction in food intake. By contrast, pair-feeding causes less-pronounced weight loss, while weight matching requires a 51% decrease in food intake. Therefore, approximately one-third of CagriSema’s weight loss efficacy arises from an effect on energy expenditure, the blunting of metabolic adaptation, which contributes to the successful treatment of obesity.